Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/142502Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Gião, T | |
| dc.creator | Saavedra, J | |
| dc.creator | Cotrina, E | |
| dc.creator | Quintana, J | |
| dc.creator | Llop, J | |
| dc.creator | Arsequell, G | |
| dc.creator | Cardoso, I | |
| dc.date.accessioned | 2022-08-01T11:21:34Z | - |
| dc.date.available | 2022-08-01T11:21:34Z | - |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1661-6596 | |
| dc.identifier.uri | https://hdl.handle.net/10216/142502 | - |
| dc.description.abstract | Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions. In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer’s disease (AD). We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aß peptides, and the proposed mechanisms underlying TTR neuroprotection in AD. We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics. | |
| dc.description.sponsorship | The group from i3S acknowledges for funding through a grant from Norte2020, Portugal (Norte-01-0145FEDER-000008- Porto Neurosciences), and Fundação Millennium bcp. The group at CIC biomaGUNE acknowledges the Spanish Ministry of Economy and Competitiveness, grant number CTQ2017-87637-R. | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.relation.ispartof | International Journal of Molecular Sciences, vol.21(6):2075 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.mesh | Alzheimer Disease / drug therapy | |
| dc.subject.mesh | Alzheimer Disease / metabolism | |
| dc.subject.mesh | Alzheimer Disease / pathology | |
| dc.subject.mesh | Amyloid beta-Peptides / metabolism | |
| dc.subject.mesh | Drug Delivery Systems | |
| dc.subject.mesh | Drug Discovery | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Prealbumin / antagonists & inhibitors | |
| dc.subject.mesh | Prealbumin / metabolism | |
| dc.title | Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
| dc.identifier.doi | 10.3390/ijms21062075 | |
| dc.relation.publisherversion | https://www.mdpi.com/1422-0067/21/6/2075 | |
| Appears in Collections: | ICBAS - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.3390-ijms21062075.pdf | 626.14 kB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
